Ryvu Therapeutics Sa · GPW:RVU
Ryvu Therapeutics Sa — Investor Presentation (September 2026)
40 slides from Ryvu Therapeutics Sa's investor presentation, September 2026
Slide 1: Corporate Presentation
Developing therapeutics at the forefront of oncology Corporate Presentation September 2026
Slide 2: Note on the presentation and forward-looking statements
Note on the presentation and forward-looking statements This document does not constitute a public offering in the meaning of the Regulation (EU) 2017/1129 of the European Parliament and of the Council, o r any other offer or invitation to acquire any Company's securities, nor the incentive to subm
Slide 3: Accelerating oncology innovation to patients
First-in-class CDK8/19i romaciclib demonstrated efficacy in post-VEN AML – high unmet need; expansion data generating in 2026 to support accelerated development Accelerating oncology First-in-class pipeline supports long-term innovation: innovation precision oncology and novel ADC payloads to patien
Slide 4: Broad pipeline addressing emerging targets in oncology
Broad pipeline addressing emerging targets in oncology PRECLINICAL AND CLINICAL PROGRAMS PARTNER / EXPECTED PROGRAM INDICATION DISCOVERY PRECLINICAL PHASE I PHASE II COLLABORATION MILESTONES R/R AML Dose expansion data RIVER-81 (combo with venetoclax) in Q426 Romaciclib (RVU120) (CDK8/19) Children's
Slide 5: Team with a strong track record of clinical development and shareholder value creation
Team with a strong track record of clinical SUPERVISORY BOARD development and shareholder value creation Piotr Romanowski, M.D. Ph.D., Chairman Tadeusz Wesołowski, Ph.D, Deputy Chairman Scott Z. Fields, M.D. Peter Smith, Ph.D Rafał Chwast, MSc Paweł Przewięźlikowski, MSc, MBA Krzysztof Brzózka, Ph
Slide 6: Romaciclib (RVU120): First-in-Class CDK8/19 Inhibitor
Romaciclib (RVU120): First-in-Class CDK8/19 Inhibitor
Slide 7: Romaciclib (RVU120): clinical-stage, first-in-class CDK8/19 kinase inhibitor
Romaciclib (RVU120): clinical-stage, first-in-class, small molecule Romaciclib CDK8/19 kinase inhibitor developed and fully-owned by Ryvu Romaciclib uniquely targets transcriptional factors Addressing high unmet need with significant clinical and commercial potential to disrupt oncogenic pathways Ac
Slide 8: Romaciclib clinical Studies
Romaciclib Development priority is to confirm activity in R/R AML 2025 2026 2027 2028 2029 2030 I II III IV I II III IV I II III IV I II III IV I II III IV I II III IV RIVER-81: Dose AML: R/R AML post-VEN (RVU120+VEN) Confirmatory part Romaciclib clinical Studies Exploratory part expansion 1L AML, u
Slide 9: Romaciclib has the potential to overcome VEN resistance and improve combination efficacy
AML Romaciclib has the potential to overcome VEN resistance and improve combination efficacy Mechanism of romaciclib & VEN synergy in AML Romaciclib with VEN in AML Resistance to VEN poses a significant clinical challenge: ~80% of patients are not eligible for effective subsequent therapy Romaciclib
Slide 10: RIVER-81: Phase II study of romaciclib in combination with venetoclax
RIVER-81: Phase II study of romaciclib in combination AML with venetoclax in VEN-refractory AML patients – dose expansion A multicenter, open-label clinical trial (RIVER-81, NCT06191263) EXPLORATORY PART 1 EXPANSION PART 2 CONFIRMATORY PART 3 Dose finding Dose-expansion Simon's 2-stage Confirmatory
Slide 11: Romaciclib induced CR/CRi in patients who failed venetoclax
AML Romaciclib induced CR/CRi in patients who failed venetoclax Dose finding: Dose-expansion: Dose finding: Dose finding: Dose finding: Cohorts 1- 3 Stage 1 Cohort 4 Cohort 6a Cohort 6b Treatment schedule RVU120 125 – 250 mg QOD RVU120 250 mg QOD RVU120 150 mg QD RVU120 200 mg QD RVU120 250 mg QD +
Slide 12: Favorable safety profile in RIVER-81 and previous studies with limited cytopenias
AML Favorable safety profile in RIVER-81 and previous studies with limited cytopenias TEAEs regardless of causality occurring in ≥10% of patients Romaciclib in combination with VEN is safe AEs All grades Grade 1 & 2 Grade 3 Grade 4 Grade 5 and tolerated in patients with VEN-failed AML Nausea 34 (58
Slide 13: Romaciclib in AML – Dose expansion initiated
AML Romaciclib in AML – Dose expansion initiated At 150 mg QD, a CR rate of 29% (2/7) Current status: data to be confirmed 01 04 with a median DoR of 156 days has been achieved in the RIVER-81 dose expansion (n ≈ 30 patients); US IND reactivated by FDA Safety and tolerability of romaciclib No releva
Slide 14: Romaciclib in myelofibrosis: clinical benefit in exploratory study
MF Romaciclib in myelofibrosis: clinical benefit in exploratory study Opportunity in myelofibrosis Romaciclib in myelofibrosis • Growing market with many patients undiagnosed or not treated • Disrupts downstream signaling events, mitigating MF symptoms • Long durations of therapy • Reduces splenomeg
Slide 15: Data in patients with myelofibrosis confirm romaciclib as a clinically active drug
MF Data in patients with myelofibrosis confirm romaciclib as a clinically active drug Safety profile of romaciclib as a single agent Significant and durable improvements 01 and in combination with RUX confirmed; 03 of myelofibrosis-associated symptoms cytopenia-sparing profile confirmed, were observ
Slide 16: High unmet need and market potential in AML
Romaciclib High unmet need and market potential in AML AML (Acute Myeloid Leukemia) • The most common, highly aggressive type of acute leukemia occurring in adults(1) • Annual incidence in the US at ~20,800 with an est. 11,220 deaths in the US in 2024 (2) Global AML Market (4) • SoC after VEN failur
Slide 17: Phase I study of romaciclib in combination with everolimus in children with medulloblastoma
Medulloblastoma Phase I study of romaciclib in combination with everolimus in children with recurrent or progressive Group 3 or 4 medulloblastoma Treatment with RVU120 alone or in combination with mTOR Pediatric medulloblastoma: the most common embryonal CNS tumor inhibition suppresses MB orthotopic
Slide 18: Romaciclib is a first-in-class CDK8/19 inhibitor accelerating to potential approval
Romaciclib Romaciclib is a first-in-class CDK8/19 inhibitor accelerating to potential approval Efficacy and safety data in AML and MF AML: efficacy demonstrated clinically in a post-VEN population with no effective options support accelerated development MF: efficacy post-JAK with disease-modifying
Slide 19: RVU305: MTA-cooperative PRMT5 inhibitor
RVU305: MTA-cooperative PRMT5 inhibitor • Best-in-class potency and selectivity • Brain-penetrant
Slide 20: RVU305: Best-in-class PRMT5 MTA-cooperative inhibitor
RVU305: Best-in-class PRMT5 MTA-cooperative inhibitor RVU305 (PRMT5i) Uncoupling PK from PD to Unlock Combination Potential in MTAP-del Cancers RVU305/PRMT5i RVU305 has best-in-class potential based on robust multiparameter optimization PRMT5 MTA-cooperative inhibitors • Antiproliferative activity:
Slide 21: RVU305 shows significant antitumor efficacy in vivo
RVU305 (PRMT5i) RVU305 shows significant antitumor efficacy in vivo Strong antitumor efficacy Complete responses demonstrated in vivo: favorable vs. MRTX1719 DoHH2 MTAP-deleted model (DLBCL) Tumor volume Tumor volume Tumor volume 4096 Individual tumor volume [mm3] 4096 RVU305, 150 mg/kg PO QD Indivi
Slide 22: RVU305 has a potentially best-in-class profile compared to clinical-stage competitors
RVU305 has a potentially best-in-class profile RVU305 (PRMT5i) compared to clinical-stage competitors • RVU305 is brain-penetrant and shows better target coverage in brain compared to AMG193 MRTX1719/ TNG462 TNG456 AMG193 RVU305 BMS-986504 • RVU305 has better selectivity Potency* +++ +++ ++ ++ +++ i
Slide 23: Ryvu Discovery Engine
Ryvu Discovery Engine • ONCO Prime • Novel ADC Payloads
Slide 24: Ryvu's discovery engine: Dual-pronged strategy
Ryvu’s discovery engine: Dual-pronged strategy with potential to generate multiple oncology medicines Novel precision oncology Next-generation ONCO Prime ADCs drug discovery platform novel ADC payloads Broad potential to discover novel precision oncology targets, Potential to improve efficacy, safet
Slide 25: Driving novel precision oncology drug discovery with ONCO Prime platform
Driving novel precision oncology drug discovery and development ONCO Prime with Ryvu’s ONCO Prime platform Discovering Novel Precision Oncology Ryvu’s CRISPR-based target Discovery Platform Targets, including Synthetic Lethal Targets Engineered Model Patient-Derived Cells (PDCs) Synthetic Common Eng
Slide 26: Initial ONCO Prime data presented in CRC
Initial ONCO Prime data presented in CRC; ONCO Prime broad applicability across oncology • Third most prevalent cancer worldwide • Estimated number of colorectal cancers in the US for 2024 are 153,000 new cases1 CRC • Diagnosed usually at an advanced stage. Mortality still remains high. Five-year su
Slide 27: ONCO Prime is accelerating the development of novel precision medicine targets
ONCO Prime is accelerating the development of novel precision ONCO Prime medicine targets, including synthetic lethal targets Modeling cancer progression High Throughput Screenings Novel Targets & Treatments APC KRAS TP53 SMAD4 Patient-derived material Ryvu’s OncoPrime platform has broad potential t
Slide 28: Novel payloads have the potential to improve efficacy and safety in next generation ADCs
ADC Payloads Novel payloads have the potential to improve efficacy and safety in next generation ADCs Approved ADCs use three main types of payloads Novel payloads have the potential to improve on… Efficacy: overcome resistance to existing payloads and potentially improve on potency Safety: expand t
Slide 29: Ryvu is developing novel ADC payloads
Ryvu is developing novel ADC payloads: ADC Payloads potential to improve efficacy and safety of next generation ADCs PAYLOAD CLASSES POTENT CYTOTOXINS IMMUNOMODULATORY IMMUNOCYTOTOXIC PAYLOADS PAYLOADS Traditional approach A newer approach Innovative approach • Example: STING (ongoing • Exploring cy
Slide 30: Ryvu has shortlisted several immunocytotoxic payloads to advance
ADC Payloads Ryvu has shortlisted several immunocytotoxic payloads to advance Based on initial screens at Ryvu, several targets have been selected as promising immunocytotoxic payloads. Some blinded examples are presented below. Low nM PoC as Single agent Pantoxic IO combo Target Drug name inhibitor
Slide 31: STING activating Antibody-Drug Conjugates
ADC Payloads STING activating Antibody-Drug Conjugates STING activating Antibody-Drug Conjugates • Proprietary STING agonist chemotype • ADC development expertise • Localized immune response • Small-molecule, non-CDN structures • Antibodies against cancer-relevant after systemic administration antig
Slide 32: Collaborations and Corporate Progress
Collaborations and Corporate Progress
Slide 33: Dapolsertib collaboration with Menarini: JASPIS-01 Phase II study in DLBCL
Dapolsertib (MEN1703) Dapolsertib collaboration with Menarini: JASPIS-01 Phase II clinical study in DLBCL • Global development and commercial rights licensed to PARTNERSHIP Menarini AGREEMENT WITH DLBCL MENARINI GROUP • As of September 2023, Ryvu has become Menarini’s operational partner for Phase I
Slide 34: Collaborations with BioNTech and Exelixis validate Ryvu's discovery platforms
Collaborations with BioNTech and Exelixis validate Ryvu’s discovery platforms and translational expertise Multi-target research collaboration on targets selected by BioNTech Partnership expanded in Q3 2025 to include clinical execution support for BioNTech’s programs in Poland Ryvu received >€50M fr
Slide 35: Keelira – Ryvu's dedicated early clinical development services business
Keelira – Ryvu’s dedicated early clinical development services business Keelira supports biotech and pharma sponsors advancing early oncology programs in Europe. CRO Plus: Clinical Execution, Strategic Advisory and Central Lab – brought together in one accountable team from planning through delivery
Slide 36: Keelira adds a complementary growth platform while protecting Ryvu's pipeline
Keelira adds a complementary growth platform while protecting Ryvu’s pipeline WITHIN RYVU THERAPEUTICS DISTINCT PROGRAM GOVERNANCE Ryvu proprietary programs Keelira client programs Ryvu’s oncology pipeline, External client programs are delivered governed and prioritized under a dedicated QMS, separa
Slide 37: Financial Results: H1 YTD 2026
Financial Results: H1 YTD 2026 H1 YTD H1 YTD € million 20251 20251 20261 Cash position as of September 10, 2026 Revenues 20.7 10.0 9.1 Partnering Grants 14.7 6.0 6.9 3.1 6.8 2.3 €14.4M (PLN 62.1M)4 In addition, as of September 23, the company Total Costs2 43.0 22.6 15.9 has secured approximately €42
Slide 38: Ryvu's Vision: 2026 key goals and financing
Ryvu’s Vision: Ryvu will improve the lives of cancer patients worldwide 2026 / KEY GOALS AND FINANCING ROMACICLIB PROGRESS SUMMARY • Romaciclib AML development (incl. potential fast-to-market strategy) • Encouraging efficacy demonstrated in AML and MF RIVER-81 Phase II study dose expansion (N=30) in
Slide 39: Ryvu equity summary
Ryvu equity summary Top Holders3 1 Paweł Przewięźlikowski (through Benevora Family Foundation) 17.2% IPO on the WSE Nov 2014, Oct 2019 2 OFE Allianz Polska 9.9% Corporate Split: Selvita and Ryvu 3 BioNTech SE 8.3% Ticker: WSE RVU 4 OFE Nationale Nederlanden 6.0% 5 Tadeusz Wesolowski with Wesolowski
Slide 40: Thank you
Thank you CONTACT DATA: Ryvu Therapeutics S.A. www.ryvu.com ryvu@ryvu.com ir@ryvu.com
Ryvu Therapeutics — Investor Presentation (September 2026) on 6ix